Literature DB >> 18795591

A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.

Abdulkadir Yildiz1, Esra Gucuk, Serkan Cay.   

Abstract

Fibrates either alone or in combination with statins have been commonly used for the treatment of high non-HDL-cholesterol levels. In addition, this type of therapy is also associated with some adverse events like rhabdomyolysis. We present the first case in the literature describing the development of both rhabdomyolysis-induced acute renal failure and thromboembolic event under the treatment of fibrate monotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795591     DOI: 10.2143/AC.63.4.2033052

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  3 in total

1.  Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.

Authors:  Ramazan Danis; Sami Akbulut; Sehmus Ozmen; Senay Arikan
Journal:  Case Rep Med       Date:  2010-07-25

Review 2.  Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.

Authors:  Dawei Wang; Yanqiu Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 3.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

Authors:  Jianyong Wu; Yan Song; Heng Li; Jianghua Chen
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.